Coronary Artery Disease Risk

Condition: Coronary Artery Disease Risk  |  Category: Cardiovascular Health  |  Reviewed by: Brian Lamkin, DO

What Is Coronary Artery Disease?

Coronary artery disease (CAD) is the progressive narrowing of the coronary arteries through atherosclerotic plaque accumulation, reducing blood flow to the heart muscle. It develops through a sequence of endothelial injury, atherogenic lipoprotein particle infiltration into the arterial wall, inflammatory amplification, foam cell formation, and plaque progression that occurs over decades before producing symptoms. The first clinical presentation is often a heart attack, meaning that by the time conventional medicine intervenes, the disease has been silently progressing for 20 to 30 years.

The critical insight of preventive cardiology is that every step of this process is driven by identifiable, measurable, and modifiable factors. Endothelial dysfunction from insulin resistance, hypertension, and oxidative stress damages the arterial lining. Atherogenic lipoproteins (measured by ApoB, not standard LDL cholesterol) penetrate the damaged endothelium. Chronic inflammation (measured by hs-CRP and Lp-PLA2) amplifies the inflammatory cascade within the plaque. Atherosclerotic plaque progresses or stabilizes based on whether these drivers are addressed or ignored.

Why Coronary Risk Assessment Matters

Common Symptoms

Root Causes: A Functional Medicine Perspective

Coronary artery disease is not random. It develops through a predictable cascade of vascular injury, lipoprotein infiltration, and inflammatory amplification. Each stage has identifiable drivers.

Endothelial Dysfunction: The First Step

Endothelial dysfunction is the initial event in coronary disease. The endothelium (inner lining of arteries) normally functions as a selective barrier that prevents lipoprotein infiltration. Insulin resistance, hypertension, oxidative stress, smoking, and hyperglycemia damage this barrier, increasing permeability to atherogenic particles. Without endothelial damage, even elevated lipoproteins have limited access to the arterial wall.

Atherogenic Lipoprotein Burden

The driver of plaque formation is the number of ApoB-containing particles (LDL, VLDL remnants, IDL) that enter the arterial wall. This is measured by ApoB concentration and LDL particle number, not by standard LDL cholesterol (which measures the cholesterol mass carried by LDL particles, not the number of particles). Two patients with identical LDL-C of 130 mg/dL can have dramatically different ApoB levels (one 90, one 140), representing dramatically different coronary risk. Lipoprotein(a), a genetically determined atherogenic and thrombotic particle, is present in 20 percent of the population and is not measured on standard panels.

Inflammatory Amplification

Chronic systemic inflammation amplifies every stage of atherosclerosis. hs-CRP reflects systemic inflammatory burden. Lp-PLA2 (lipoprotein-associated phospholipase A2) is a vascular-specific inflammatory enzyme produced within atherosclerotic plaque, making it a marker of active plaque inflammation. The CANTOS trial demonstrated that reducing inflammation (IL-1beta inhibition) reduced cardiovascular events independently of lipid lowering, confirming inflammation as a causal contributor, not just a bystander.

Insulin Resistance: The Metabolic Multiplier

Insulin resistance produces the atherogenic triad (elevated triglycerides, low HDL, small dense LDL), endothelial dysfunction, chronic inflammation, hypertension, and prothrombotic state simultaneously. It is the single upstream metabolic driver that produces the majority of modifiable coronary risk factors. Addressing insulin resistance addresses multiple coronary risk factors through a single mechanism.

Conventional vs Functional Medicine Approach

Key Labs to Evaluate

How to Interpret These Labs Together

Common Patterns Seen in Patients

• The 45-year-old with "normal cholesterol" and a coronary calcium score of 180: LDL-C 118. Standard lipid panel unremarkable. Family history of early CAD (father had MI at 52). Coronary calcium score: 180 (above 90th percentile for age). ApoB 135 (elevated). Lp(a) elevated (genetic risk). The standard panel missed the disease. The calcium score confirmed it. The advanced lipids identified the mechanism. Aggressive ApoB reduction and Lp(a) management initiated.
• The patient on a statin with persistent inflammation: LDL-C reduced from 160 to 72 on rosuvastatin 20mg. But hs-CRP 3.4 (persistent inflammation). Fasting insulin 16 (insulin resistance). The statin successfully lowered LDL cholesterol, but the inflammatory driver and the metabolic driver are untreated. Adding anti-inflammatory protocols and insulin sensitization addressed the residual risk that the statin alone could not.
• The metabolic syndrome patient with no cardiac evaluation: BMI 33, fasting insulin 24, triglycerides 280, HDL 34, HbA1c 5.9. No cardiologist referral because "cholesterol is not that bad" (LDL-C 125). TG/HDL ratio 8.2 (severely atherogenic). This patient has the highest-risk lipoprotein pattern in cardiology, and it is invisible on a standard cholesterol panel. Insulin sensitization is the primary cardiovascular intervention.

Treatment and Optimization Strategy

Comprehensive Coronary Risk Reduction

What Most Doctors Miss

• Standard cholesterol panels miss the most important variables: ApoB (particle count) predicts coronary risk better than LDL-C. Lp(a) (genetic risk) is present in 20 percent of the population and never measured. Oxidized LDL (modified atherogenic particles) is not on standard panels. Advanced lipid testing should be standard for anyone with coronary risk.
• Coronary calcium scoring detects disease decades before stress tests: stress tests detect hemodynamically significant stenosis (70+ percent). Coronary calcium detects any calcified plaque. A patient with a CAC of 200 and a normal stress test has significant coronary disease that the stress test cannot identify.
• Insulin resistance produces the most dangerous lipoprotein pattern: the atherogenic triad (high TG, low HDL, small dense LDL) is driven by insulin resistance. Fasting insulin is not part of standard cardiac evaluation despite identifying the metabolic driver of the highest-risk lipoprotein pattern.
• Inflammation is a causal contributor, not just a marker: the CANTOS and COLCOT trials demonstrated that anti-inflammatory intervention reduces cardiovascular events independently of lipid lowering. Inflammation should be measured and treated as a coronary risk factor.

When to Seek Medical Care

If you have a family history of early coronary disease (first-degree relative with event before age 55 in men or 65 in women), metabolic syndrome components (insulin resistance, hypertension, dyslipidemia), or if you want to know your actual coronary disease status rather than your estimated risk score, comprehensive cardiovascular evaluation with advanced lipids, inflammatory markers, metabolic assessment, and coronary calcium scoring is warranted.

Recommended Testing

Frequently Asked Questions

How The Lamkin Clinic Approaches Coronary Risk

At The Lamkin Clinic, coronary risk evaluation includes advanced lipid testing (ApoB, LDL particle number/size, Lp(a), oxidized LDL), inflammatory markers (hs-CRP, Lp-PLA2), comprehensive metabolic assessment (fasting insulin, HOMA-IR, triglyceride/HDL ratio), and coronary calcium scoring when indicated. Treatment targets ApoB reduction, inflammatory burden reduction, insulin sensitization, endothelial restoration, and blood pressure optimization to prevent coronary events at the earliest stage of disease, not after the first event has already occurred.

Related Conditions

Related Symptoms